Principal Financial Group Inc. reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 9.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,963 shares of the biopharmaceutical company’s stock after selling 2,482 shares during the period. Principal Financial Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,695,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of the stock. Nuveen Asset Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 5,486.1% in the third quarter. Nuveen Asset Management LLC now owns 16,593,268 shares of the biopharmaceutical company’s stock worth $3,321,309,000 after acquiring an additional 16,296,223 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.2% during the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after buying an additional 126,373 shares during the last quarter. State Street Corp boosted its position in shares of Alnylam Pharmaceuticals by 2.1% during the first quarter. State Street Corp now owns 2,909,490 shares of the biopharmaceutical company’s stock valued at $475,091,000 after buying an additional 59,101 shares during the last quarter. Invesco Ltd. boosted its position in shares of Alnylam Pharmaceuticals by 8.8% during the first quarter. Invesco Ltd. now owns 968,755 shares of the biopharmaceutical company’s stock valued at $158,187,000 after buying an additional 78,665 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.7% during the third quarter. UBS Asset Management Americas Inc. now owns 603,532 shares of the biopharmaceutical company’s stock valued at $120,803,000 after buying an additional 10,310 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several research firms recently commented on ALNY. Oppenheimer dropped their price objective on Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating on the stock in a research report on Friday, February 24th. BMO Capital Markets raised Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $200.00 to $250.00 in a research report on Friday, May 5th. HC Wainwright reissued a “buy” rating and issued a $415.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 3rd. Sanford C. Bernstein started coverage on Alnylam Pharmaceuticals in a research report on Tuesday, March 21st. They issued an “outperform” rating and a $243.00 target price on the stock. Finally, Citigroup dropped their target price on Alnylam Pharmaceuticals from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, February 24th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $247.20.
Alnylam Pharmaceuticals Trading Up 1.2 %
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.97) by $0.57. The business had revenue of $319.29 million during the quarter, compared to analysts’ expectations of $312.53 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The firm’s revenue for the quarter was up 49.7% compared to the same quarter last year. During the same quarter last year, the business posted ($2.00) EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.46 earnings per share for the current year.
Insider Buying and Selling at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,615 shares of the firm’s stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total transaction of $1,481,802.85. Following the completion of the transaction, the chief executive officer now owns 30,332 shares in the company, valued at approximately $5,902,303.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Yvonne Greenstreet sold 7,615 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $1,481,802.85. Following the completion of the transaction, the chief executive officer now owns 30,332 shares in the company, valued at approximately $5,902,303.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jeffrey V. Poulton sold 977 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $190,114.43. Following the completion of the transaction, the chief financial officer now owns 11,706 shares of the company’s stock, valued at approximately $2,277,870.54. The disclosure for this sale can be found here. Insiders sold 35,871 shares of company stock worth $7,131,842 in the last quarter. 1.40% of the stock is owned by corporate insiders.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.
Read More
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- MarketBeat Week in Review – 5/22 – 5/26
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
